Navigation Links
Roche's Sequence Capture Technology Used to Identify SMPX Mutations Underlying Human Hereditary Hearing Loss
Date:1/12/2012

MADISON, Wisconsin, January 12, 2012 /PRNewswire/ --

Hereditary hearing loss is the most common sensory disorder in humans. A German research team led by Ingo Kurth from the Institute of Human Genetics at the University Hospital Jena, Germany, used a number of different methods, including Roche's NimbleGen Custom Sequence Capture 385K array to identify the gene mutated in the disease locus of the X-chromosome of a Spanish family with hereditary hearing loss (1).

Targeted enrichment was performed by the German Service Provider ATLAS Biolabs GmbH. In particular, the DNA of two affected males was subjected to target enrichment. Subsequent sequencing analysis at the Cologne Center for Genomics (CCG) resulted in the identification of a total of 3858 and 3443 X-chromosomal variants for each of these two individuals. Furthermore, a nonsense mutation in the small muscle protein, X-linked (SMPX) of the affected individuals had been detected. Nonsense mutations are significant, because they are point mutations in a sequence of DNA that cause a premature stop codon, or a nonsense codon in the transcribed mRNA, resulting in a truncated, incomplete, and usually nonfunctional protein. Based on their findings, the authors propose that long-term maintenance of mechanically stressed inner ear cells critically depends on SMPX function.

The NimbleGen Sequence Capture technology is a sophisticated process for the parallel enrichment of selected genomic regions from complex human genomic DNA. Sequence Capture allows enrichment of target regions in a single experiment, replacing the need to perform numerous PCR reactions. The efficiencies of parallel enrichment are an ideal complement for cost-effective, high throughput next-generation sequencing.

  1. Huebner et al., American Journal of Human Genetics, Vol. 88: 621-627, May 13, 2011

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: http://www.roche.com.

For life science research only.  Not for use in diagnostic procedures.

NIMBLEGEN and SEQCAP are trademarks of Roche.


Other brands or product names are trademarks of their respective holders.

Roche Diagnostics
Dr. Burkhard Ziebolz
Tel.: +49-(0)8856-604830
E-Mail: burkhard.ziebolz@roche.com

Roche NimbleGen
Kary Staples
Tel.: +1-608-218-7623
E-Mail: kary.staples@roche.com



'/>"/>
SOURCE Roche Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
2. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
3. Rochester Medical Announces Fourth Quarter 2009 Earnings Conference Call Thursday, November 5th 2009
4. Rochester Medical Reports Fourth Quarter and Annual Results and Announces Final Medicare Approval for Reimbursement for the FEMSOFT(R) Insert
5. Rochester Medical Announces First Quarter 2010 Earnings Conference Call Tuesday, January 26, 2010
6. Rochester Medical Corporation Honored by Premier Healthcare Alliance for Exceptional Supplier Performance
7. AstraZeneca Joins Rochester Initiative to Further Cardiac Safety
8. Rochester Medical Announces Fourth Quarter 2010 Earnings Conference Call Thursday, November 4, 2010
9. Rochester Medical Reports Fourth Quarter and Year-End Results
10. Rochester Medical Corporation Announces Agreement to Acquire Laprolan B.V.
11. Rochester Medical Announces First Quarter 2011 Earnings Conference Call Tuesday, January 25, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... 29, 2016 ReportsnReports.com adds ... market research report that provides an overview of ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
(Date:4/29/2016)... , April 29, 2016 ... glyco-biology expertise, today announces the appointment of Dr. ... Dr. Zurlo is an oncologist with many years clinical ... and biotechnology industries. His last role was at Mologen ... of the Executive Board. Previously Dr. Zurlo held various ...
(Date:4/28/2016)... 28, 2016  While Abbott,s announced purchase of ... valve repair and stent business, healthcare research firm ... more firmly into patient monitoring.  Kalorama said that ... device areas, with double-digit growth expected the next ... Advanced Remote Patient Monitoring . Abbott Laboratories ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, ... the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, the “Rural ... (R - Cumming), offers a 70% tax credit to individuals and corporations which donate ...
(Date:4/29/2016)... Fort Stewart, GA (PRWEB) , ... April 29, 2016 , ... ... on Monday, May 16, 2016, at its new location in the Exchange Furniture Mall ... including a raffle for a 50-inch Samsung Smart TV. Plus attendees will have the ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... announces the Gyrociser, an exercise invention which aids in proper muscle development. , ... Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has threatened the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces that Boston Medical ... neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse ... is a newly patented safety device secured by nasal surgeons onto the floor of ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... print media enterprise focused entirely on patients with cancer, today announced that Lynne ... chosen as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which ...
Breaking Medicine News(10 mins):